Cargando…

Screening of an FDA-Approved Drug Library with a Two-Tier System Identifies an Entry Inhibitor of Severe Fever with Thrombocytopenia Syndrome Virus

Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging tick-borne bunyavirus that causes severe disease in humans with case-fatality rates of up to 30%. There are currently very limited treatment options for SFTSV infection. We conducted a drug repurposing program by establishing a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Shuofeng, Chan, Jasper Fuk-Woo, Ye, Zi-Wei, Wen, Lei, Tsang, Terance Gi-Wai, Cao, Jianli, Huang, Jingjing, Chan, Chris Chun-Yiu, Chik, Kenn Ka-Heng, Choi, Garnet Kwan-Yue, Cai, Jian-Piao, Yin, Feifei, Chu, Hin, Liang, Mifang, Jin, Dong-Yan, Yuen, Kwok-Yung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520937/ https://www.ncbi.nlm.nih.gov/pubmed/31027241 http://dx.doi.org/10.3390/v11040385

Ejemplares similares

Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system
por: Yuan, Shuofeng, et al.
Publicado: (2020)

Severe fever with thrombocytopenia syndrome virus (SFTSV)-host interactome screen identifies viral nucleoprotein-associated host factors as potential antiviral targets
por: Cao, Jianli, et al.
Publicado: (2021)

Metabolic Profiling Reveals Significant Perturbations of Intracellular Glucose Homeostasis in Enterovirus-Infected Cells
por: Zou, Zijiao, et al.
Publicado: (2020)

Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19)
por: Yuan, Shuofeng, et al.
Publicado: (2020)

In silico structure-based discovery of a SARS-CoV-2 main protease inhibitor
por: Wen, Lei, et al.
Publicado: (2021)

1899. The Cellular Kinase Inhibitor OSU-03012 Inhibits Enterovirus 71 In Vitro
por: Chan, Jasper, et al.
Publicado: (2018)

918. Identification of novel druggable host targets for Middle East respiratory syndrome coronavirus using a quantitative phosphoproteomics approach
por: Chan, Jasper F W, et al.
Publicado: (2023)

hnRNP C modulates MERS-CoV and SARS-CoV-2 replication by governing the expression of a subset of circRNAs and cognitive mRNAs
por: Zhang, Xi, et al.
Publicado: (2022)

Vemurafenib Inhibits Enterovirus A71 Genome Replication and Virus Assembly
por: Hu, Bodan, et al.
Publicado: (2022)

Targeting SUMO Modification of the Non-Structural Protein 5 of Zika Virus as a Host-Targeting Antiviral Strategy
por: Zhu, Zheng, et al.
Publicado: (2019)

The celecoxib derivative kinase inhibitor AR-12 (OSU-03012) inhibits Zika virus via down-regulation of the PI3K/Akt pathway and protects Zika virus-infected A129 mice: A host-targeting treatment strategy
por: Chan, Jasper Fuk-Woo, et al.
Publicado: (2018)

SARS-CoV-2 infection induces inflammatory bone loss in golden Syrian hamsters
por: Qiao, Wei, et al.
Publicado: (2022)

Author Correction: SARS-CoV-2 infection induces inflammatory bone loss in golden Syrian hamsters
por: Qiao, Wei, et al.
Publicado: (2022)

Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library
por: Wang, Peilin, et al.
Publicado: (2018)

In Silico Structure-Based Design of Antiviral Peptides Targeting the Severe Fever with Thrombocytopenia Syndrome Virus Glycoprotein Gn
por: Yuan, Shuo-Feng, et al.
Publicado: (2021)

A Comprehensive Map of FDA-Approved Pharmaceutical Products
por: Zhong, Hao, et al.
Publicado: (2018)

Development of Three-Dimensional Human Intestinal Organoids as a Physiologically Relevant Model for Characterizing the Viral Replication Kinetics and Antiviral Susceptibility of Enteroviruses
por: Tsang, Jessica Oi-Ling, et al.
Publicado: (2021)

Unveiling some FDA-approved drugs as inhibitors of the store-operated Ca(2+) entry pathway
por: Rahman, Saifur, et al.
Publicado: (2017)

P21-activated kinase 1 (PAK1)-mediated cytoskeleton rearrangement promotes SARS-CoV-2 entry and ACE2 autophagic degradation
por: Liu, Ming, et al.
Publicado: (2023)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges
por: Füzéry, Anna K, et al.
Publicado: (2013)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Lipidomic Profiling Reveals Significant Perturbations of Intracellular Lipid Homeostasis in Enterovirus-Infected Cells
por: Yan, Bingpeng, et al.
Publicado: (2019)

Cellular Sensors and Viral Countermeasures: A Molecular Arms Race between Host and SARS-CoV-2
por: Sun, Haoran, et al.
Publicado: (2023)

Phosphatidic acid phosphatase 1 impairs SARS-CoV-2 replication by affecting the glycerophospholipid metabolism pathway
por: Yan, Bingpeng, et al.
Publicado: (2022)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Targeting papain-like protease for broad-spectrum coronavirus inhibition
por: Yuan, Shuofeng, et al.
Publicado: (2022)

Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection
por: Ye, Zi-Wei, et al.
Publicado: (2021)

Pathogenicity of SARS-CoV-2 Omicron BA.1.1 in hamsters
por: Chan, Jasper Fuk-Woo, et al.
Publicado: (2022)

A lethal mouse model using a mouse-adapted SARS-CoV-2 strain with enhanced binding to mouse ACE2 as an important platform for COVID-19 research
por: Chu, Hin, et al.
Publicado: (2021)

STAT2-dependent restriction of Zika virus by human macrophages but not dendritic cells
por: Yang, Dong, et al.
Publicado: (2021)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA-approved medications that impair human spermatogenesis
por: Ding, Jiayi, et al.
Publicado: (2016)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021)

FDA-Approved Oximes and Their Significance in Medicinal Chemistry
por: Dhuguru, Jyothi, et al.
Publicado: (2022)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dog2nujcljrvv3967sitpc8urp